China’ Simcere To Sell Its 35% Stake In Shanghai Celgen
This article was originally published in PharmAsia News
China’sSimcere Pharmaceutical Group plans to sell its 35% stake in Shanghai Celgen Bio-Pharmaceutical Co. Ltd. for $48 million, exiting a deal signed in 2009.
You may also be interested in...
China's Simcere Looks To Move Past Vaccine Troubles, Focuses On New GMP Requirements, Partnering With Big Pharma
BEIJING - Leading Chinese drug maker Simcere Pharmaceutical Group, which develops innovative medicines, first-to-market generics and biosimilars, reported this week that its earnings for 2010 skyrocketed, despite its takeover of a vaccine producer that was slapped with substantial fines last year for turning out a "substandard rabies vaccine.
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.